Selected Protease Inhibitors/Rifabutin; Rifapentine
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Serious. These medicines may interact and cause very harmful effects. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
When these two medicines are taken together, your body may not process them properly.
What might happen:
Your blood levels of rifabutin may increase and cause harmful effects. Rifabutin and rifapentine may decrease the levels of some protease inhibitors, which may decrease their effectiveness.
What you should do about this interaction:
Make sure that your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these medicines together. If you experience a persistent sore throat or fever, contact your doctor. The dose of your medicines may need adjusting.Your healthcare professionals may already be aware of this drug interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
1.Agenerase (amprenavir) Australian prescribing information. GlaxoSmithKline Australia Pty Ltd. November 24, 2004.
2.Agenerase (amprenavir) summary of product characteristics. GlaxoSmithKline UK January 18, 2005.
3.Agenerase (amprenavir) Capsules US prescribing information. GlaxoSmithKline May, 2005.
4.Reyataz (atazanavir sulfate) Australian product information. Bristol-Myers Squibb Pharmaceuticals January 8, 2004.
5.Reyataz (atazanavir) UK summary of product characteristics. Bristol-Myers Squibb Pharmaceuticals Limited September 8, 2008.
6.Reyataz (atazanavir sulfate) US prescribing information. Bristol-Myers Squibb Company August, 2013.
7.Telzir (fosamprenavir calcium) Australian prescribing information. GlaxoSmithKline Australia Pty Ltd. November 24, 2004.
8.Telzir (fosamprenavir calcium) UK summary of product characteristics. GlaxoSmithKline UK August 8th, 2008.
9.Lexiva (fosamprenavir calcium) US prescribing information. GlaxoSmithKline February, 2013.
10.Crixivan (indinavir sulfate) Australian prescribing information. Merck Sharp & Dohme (Australia) Pty Ltd. August 11, 2003.
11.Crixivan (indinavir sulfphate) UK summary of product characteristics. Merck Sharp & Dohme Limited September, 2008.
12.Crixivan (indinavir sulfate) US prescribing information. Merck & Co., Inc. February, 2011.
13.Kaletra (lopinavir/ritonavir) UK summary of product characteristics. Abbott Laboratories, Limited July 11, 2008.
14.Kaletra (lopinavir/ritonavir tablets) US prescribing information. Abbott Laboratories January, 2013.
15.Viracept (nelfinavir mesylate) Australian prescribing information. Roche Products Pty Ltd. October 26, 2000.
16.Viracept (nelfinavir mesylate) US prescribing information. Agouron Pharmaceuticals, Inc. May, 2013.
17.Viracept (nelfinavir mesylate) UK summary of product characteristics. Roche Products Limited August 4, 2008.
18.Kaletra (lopinavir/ritonavir) Australian prescribing information. Abbott Australasia Pty. Ltd. April 1, 2004.
19.Aptivus (tipranavir) US prescribing information. Boehringer Ingelheim Pharmaceuticals, Inc. February, 2012.
20.Polk RE, Brophy DF, Israel DS, Patron R, Sadler BM, Chittick GE, Symonds WT, Lou Y, Kristoff D, Stein DS. Pharmacokinetic Interaction between amprenavir and rifabutin or rifampin in healthy males. Antimicrob Agents Chemother 2001 Feb;45(2):502-8.
21.Prezista (darunavir) UK Summary of product characteristics. Janssen-Cilgat LTD August 8, 2008.
22.Prezista (darunavir) Canadian prescribing information. Jannsen-Ortho June, 2008.
23.Prezista (darunavir) US prescribing information. Tibotec Inc. February, 2013.
24.Boulanger C, Hollender E, Farrell K, Stambaugh JJ, Maasen D, Ashkin D, Symes S, Espinoza LA, Rivero RO, Graham JJ, Peloquin CA. Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis. Clin Infect Dis 2009 Nov 1;49(9):1305-11.
25.Kraft WK, McCrea JB, Winchell GA, Carides A, Lowry R, Woolf EJ, Kusma SE, Deutsch PJ, Greenberg HE, Waldman SA. Indinavir and rifabutin drug interactions in healthy volunteers. J Clin Pharmacol 2004 Mar; 44(3):305-13.
26.Hamzeh FM, Benson C, Gerber J, Currier J, McCrea J, Deutsch P, Ruan P, Wu H, Lee J, Flexner C. Steady-state pharmacokinetic interaction of modified-dose indinavir and rifabutin. Clin Pharmacol Ther 2003 Mar; 73(3):159-69.
27.la Porte CJ, Sabo JP, Elgadi M, Cameron DW. Interaction studies of tipranavir-ritonavir with clarithromycin, fluconazole, and rifabutin in healthy volunteers. Antimicrob Agents Chemother 2009 Jan;53(1):162-73.
28.Invirase (saquinavir mesylate) US prescribing information. Roche Laboratories, Inc. February, 2012.
29.Phansalkar S, Desai AA, Bell D, Yoshida E, Doole J, Czochanski M, Middleton B, Bates DW. High-priority drug-drug interactions for use in electronic health records. J Am Med Inform Assoc 2012 Sep-Oct; 19(5):735-43.